定义免疫耐受诱导对美国重型A型血友病队列中临床相关结局的影响
该研究利用2013至2017年美国血友病治疗中心社区计数登记数据,分析3659例重型A型血友病患者中接受免疫耐受诱导(ITI)与临床结局的关联。576例抑制物患者中485例(84%)接受ITI,其中299例(61.7%)成功。接受ITI者治疗性出血、慢性疼痛更少,功能与教育程度更好;ITI成功与更少治疗性出血、医疗使用、慢性疼痛、更好功能及更少缺课/缺勤相关;死亡率与ITI无关。
要点
- 接受ITI者较未接受者治疗性出血更少、慢性疼痛更少、功能更好、教育程度更高。
- ITI成功较部分成功或失败与更少治疗性出血、医疗使用、慢性疼痛、更好功能及更少缺课/缺勤相关。
- 死亡率与是否接受ITI无关,与ITI是否成功也无关。
核心结论
- 接受ITI,尤其是ITI成功,可改善临床结局但不改善死亡率。
- 这些发现支持关于启动ITI的决策并为未来临床试验提供信息。
研究设计与样本
- 利用2013至2017年美国血友病治疗中心社区计数登记数据,纳入3659例重型A型血友病患者,进入登记时中位年龄21岁。
- 576例抑制物患者中485例(84%)接受ITI,ITI成功299例(61.7%),部分成功95例(19.5%),失败91例(18.7%)。
- 采用多变量逻辑回归、负二项和泊松模型分析。
主要发现
- 接受ITI者较未接受ITI者治疗性出血更少、慢性疼痛更少、功能更好、教育程度更高。
- ITI成功较部分成功和失败与更少治疗性出血、更少医疗使用、更少慢性疼痛、更好功能及更少缺课或缺勤相关。
- 死亡率与ITI无关,无论ITI是否成功。
- ITI成功者治疗性出血、慢性疼痛和医疗使用率与无抑制物者相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although the near-term benefit of immune tolerance induction (ITI) for the treatment of people with severe hemophilia A with inhibitor is apparent, the magnitude of the longer-term impact of ITI on clinical outcomes remains undefined. We examined the association between receiving ITI and the success of ITI on clinical outcomes including (1) clinical events, (2) health care use, (3) quality of life/function, (4) socioeconomic status, and (5) death, using the Community Counts (CC) registry of US Hemophilia Treatment Centers between 2013 and 2017. Multivariate logistic regression, negative binomial, and Poisson models were used. Included in this study were 3659 people with severe hemophilia A with median age of 21 years when entering the CC registry. Among 576 participants with inhibitors, 485 had received ITI (84%). ITI was successful in 299 (61.7%) and partially successful or failed in 95 (19.5%) or 91 (18.7%), respectively. Those that received ITI had fewer treated bleeds, less chronic pain, better function, and higher educational attainment than those not receiving ITI. Successful vs partially successful and failed ITI was associated with fewer treated bleeds, less health care use, less chronic pain, better function, and fewer missed days of school or work. Mortality was not associated with ITI, regardless of its success. Those with successful ITI had similar rates of treated bleeds, chronic pain, and health care use as those with no inhibitors. Undergoing ITI, particularly if successful, improved clinical outcomes but not mortality. These findings support decision making regarding initiation of ITI and inform future clinical trials.
引用
- Kempton CL, Fedewa SA. Defining the impact of immune tolerance induction on clinically relevant outcomes in a US cohort of severe hemophilia A. Blood Adv. 2024. PMID: 38163316. doi:10.1182/bloodadvances.2023011974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。